• January 18, 2021

H1 2020 Pipeline Review on Huntington Disease - ResearchAndMarkets.com - Odessa American: Business

e-Edition Subscribe

H1 2020 Pipeline Review on Huntington Disease - ResearchAndMarkets.com

Font Size:
Default font size
Larger font size

Posted: Thursday, December 31, 2020 5:16 am

DUBLIN--(BUSINESS WIRE)--Dec 31, 2020--

The "Huntington Disease - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 13, 62, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 3 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Huntington Disease - Overview
  • Huntington Disease - Therapeutics Development
  • Huntington Disease - Therapeutics Assessment
  • Huntington Disease - Companies Involved in Therapeutics Development
  • Huntington Disease - Drug Profiles
  • Huntington Disease - Dormant Projects
  • Huntington Disease - Discontinued Products
  • Huntington Disease - Product Development Milestones
  • Appendix

Companies Mentioned

  • Acen Regenerative Medicine Sci-Tech Co Ltd
  • AcuraStem Inc
  • Adeptio Pharmaceuticals Ltd
  • AFFiRiS AG
  • Alkermes Plc
  • Allianz Pharmascience Ltd
  • Alsonex Pty Ltd
  • Anima Biotech Inc
  • Annexon Inc
  • Armgo Pharma Inc
  • ArunA Biomedical Inc
  • Asdera LLC
  • Asklepios BioPharmaceutical Inc
  • Avergen Pharmaceuticals GmbH
  • Azevan Pharmaceuticals Inc
  • BrainStorm Cell Therapeutics Inc
  • Brainvectis SAS
  • Celon Pharma SA
  • Chaperone Pharma BV
  • Chaperone Therapeutics Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Cleave Therapeutics Inc
  • Collaborative Medicinal Development LLC
  • Curyx Bio Inc
  • DanPET AB
  • Dystrogen Therapeutics SA
  • Emerald Health Sciences Inc
  • Enzerna Biosciences LLC
  • Evotec SE
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Genervon Biopharmaceuticals LLC
  • Hope Biosciences LLC
  • Immungenetics AG
  • InnoMedica Holding AG
  • Krisani Bio Sciences Pvt Ltd
  • Living Cell Technologies Ltd
  • Locana Inc
  • Medesis Pharma SA
  • MindImmune Therapeutics Inc
  • Mitochon Pharmaceuticals Inc
  • Mitoconix Bio Ltd
  • Mitokinin LLC
  • MMJ International Holdings Corp
  • NeuBase Therapeutics Inc
  • NeuExcell Therapeutics Inc
  • Neurimmune Holding AG
  • Neurodon LLC
  • NeuroNascent Inc
  • New World Laboratories Inc
  • NLS Pharma Group
  • Novartis AG
  • Nuredis Inc
  • And Many More Companies!

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w6xazx

View source version on businesswire.com:https://www.businesswire.com/news/home/20201231005082/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/31/2020 06:16 AM/DISC: 12/31/2020 06:16 AM


© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Humidity: 56%
Winds: S at 8mph
Feels Like: 34°

Your Extended Forecast


High 59°/Low 36°
Mainly clear. Lows overnight in the mid 30s.


High 69°/Low 36°
Abundant sunshine. Highs in the upper 60s and lows in the mid 30s.


High 44°/Low 36°
Mostly cloudy. Highs in the mid 40s and lows in the mid 30s.


High 50°/Low 41°
Mostly cloudy. Highs in the low 50s and lows in the low 40s.
Online Features

Pet Central


Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>



Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>



Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>



Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>

  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.